Stay updated on Pembrolizumab for EGFR+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab for EGFR+ NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The clinical trial record for pembrolizumab in advanced EGFR-mutant non-small cell lung cancer is available again, with its study details, eligibility criteria, outcomes, results, and supporting documents.
    Difference
    49%
    Check dated 2026-11-09T13:58:08.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T15:46:35.000Z thumbnail image
  3. Check
    16 days ago
    Change Detected
    Summary
    A general NIH banner announces website transition updates and says agencies are using “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-26T15:13:58.000Z thumbnail image
  4. Check
    23 days ago
    Change Detected
    Summary
    The footer’s ClinicalTrials.gov revision identifier changed from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-19T14:52:09.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The site revision identifier in the footer changed from v3.7.0 to v3.7.1 while the page continued to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-12T14:55:32.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error, replacing the previous content and removing several study documents and related links from the page.
    Difference
    19%
    Check dated 2026-09-21T22:09:29.000Z thumbnail image

Stay in the know with updates to Pembrolizumab for EGFR+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for EGFR+ NSCLC Clinical Trial page.